Basement Membrane Remodeling Fuels NSCLC Invasion, Treatment Resistance

The layer of matrix separating lung epithelium from the tissue beneath it has spent decades treated as inert scaffolding. In non–small cell lung cancer (NSCLC), it behaves more like a signaling switchboard: its shifting composition drives tumor invasion, shapes metastatic routes, and can determine whether a targeted or immune therapy still works.

A Structural Layer Overlooked in NSCLC

The basement membrane, the thin collagen- and laminin-rich sheet anchoring lung epithelium to the tissue beneath it, has been treated more as inert scaffolding than as an active participant in disease, according to a review by researchers at the Garvan Institute of Medical Research and UNSW Sydney.¹ That blind spot matters most in NSCLC, about 77% of the estimated 229,410 lung cancer cases projected in the US this year; lung cancer remains the country's leading cause of cancer death, causing roughly 1 in 5 cancer deaths overall.²

Basement membrane changes begin well before invasive cancer takes hold, the authors noted. Its thickness increases in preneoplastic basal and goblet cell hyperplasia, and the degree of dysplasia in carcinoma in situ lesions correlates positively with basement membrane fragmentation, underscoring the structure's role in maintaining normal epithelial function.

Basement Membrane Biology From Development to Malignancy

Published in the American Journal of Physiology-Cell Physiology, the review draws on preclinical, translational, and clinical literature spanning lung development, injury repair, and cancer progression rather than presenting new patient data. The authors organize basement membrane function around 3 integrated mechanisms: compositional specificity, where collagen, laminin, nidogen, and proteoglycan combinations encode tissue-specific instructions; biomechanical coupling, where matrix stiffness transduces mechanical into biochemical signals; and temporal remodeling, where turnover creates windows of cellular plasticity during development, repair, and disease.

That same compositional shift defines what happens once a tumor forms. In established lung tumors, the extracellular matrix, including basement membrane components, is substantially remodeled in a histologic subtype-specific manner, with existing basement membrane restructured and new components deposited within the tumor microenvironment.

Collagen and Laminin Shifts Track Tumor Invasion

Compared with healthy lung tissue, the collagen IV network in tumors becomes fragmented or downregulated, a pattern that can vary within a single tumor. A fragmented network is associated with poor prognosis in stage I NSCLC, while loss of collagen IV correlates with increased lymph node metastasis. Newly synthesized collagen IV deposited by specific cancer-associated fibroblasts forms what the authors describe as a pseudo–basement membrane between tumor cells and surrounding stroma in both adenocarcinoma and squamous NSCLC.

Other basement membrane proteins move in the opposite direction. Collagen types XVII and XVIII are both overexpressed in NSCLC tumor tissue compared with healthy lung, and higher collagen XVIII expression is independently associated with poor prognosis regardless of tumor size or lymph node status. The glycoprotein tenascin C is focally overexpressed in primary and secondary lung adenocarcinoma, where high expression correlates with poor patient outcome, driven partly by the Nkx2-1 transcription factor in KRAS-driven tumors. Fibronectin is likewise increased in NSCLC relative to nontumor tissue, where it promotes cancer cell migration and invasion via α5β1 integrin and downstream focal adhesion kinase (FAK) signaling.

Basement Membrane Signals Shape Treatment Response

The basement membrane's influence extends into how tumors respond to therapy. Laminin γ2 enrichment supports the outgrowth of primary and brain-metastatic epidermal growth factor receptor (EGFR)-mutant NSCLC cell lines under osimertinib and gefitinib, and its overexpression is separately associated with poor overall survival in patients treated with immune checkpoint blockade. In lung tumors, transforming growth factor (TGF) β-stimulated cancer-associated fibroblasts elevate intratumoral laminin γ2, which limits T-cell infiltration and reduces the efficacy of anti–PD-1 therapy.

“Consequently, therapeutic progress depends on transitioning from broad matrix inhibition toward precise normalization strategies that aim to adjust these signals and restore the original homeostatic function of the basement membrane,” the researchers wrote.

Basement membrane biomarkers may help predict who benefits from immunotherapy. A basement membrane–enriched gene signature in lung adenocarcinoma, marked by downregulation of the type IV collagen genes COL4A3 and COL4A4 alongside upregulation of COL18A1, has been linked to poor response to checkpoint blockade. Conversely, circulating antibodies against collagen XVII, also known as BP180, arising during PD-1/PD-L1 checkpoint therapy are associated with better treatment response and overall survival in patients with NSCLC.

Matrix-Targeting Strategies and Open Questions

Translating that biology into treatment remains early. Strategies now in development include PXS-5120A, a lysyl oxidase inhibitor shown preclinically to reduce collagen cross-linking and matrix stiffening, and 4-methylumbelliferone, which blocks hyaluronan synthesis and has sensitized lung cancer stem cells to paclitaxel in preclinical models. A recombinant, collagen XVIII–derived form of endostatin has improved disease control rates when added to platinum doublet chemotherapy in NSCLC.

Fundamental questions remain unresolved, the authors acknowledged. Current proteomic approaches can catalog basement membrane components but cannot resolve their spatial organization or assembly patterns, and the field lacks tools to monitor turnover in real time or predict which compositional changes drive invasion versus normal repair. Closing those gaps, they concluded, will be necessary before basement membrane–targeted or –informed strategies can complement conventional tumor-directed therapy for clinicians and patients managing NSCLC.

References

1. Yoo D, Cox TR, Parker AL. Forgotten foundations: basement membranes in lung function and cancer. Am J Physiol Cell Physiol. 2026;330:C1574-C1593. doi:10.1152/ajpcell.00599.2025

2. Key statistics for lung cancer. American Cancer Society. Updated 2026. Accessed August 20, 2026. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html